Add BrightSurf on Google Email

A formidable type of childhood cancer gets added to highly regarded library of treatment recommendations

The new NCCN Guidelines for Pediatric Bone Sarcoma focus on Ewing sarcoma and other undifferentiated round cell sarcomas, aiming to provide clear medical roadmaps for patients and their families. With a 5-year survival rate of 81% for early-stage diagnosis, these guidelines can help ensure teenagers receive optimal treatment and support.

New AI platform could help cancer survivors get personalized support between doctor visits

A new AI platform, Precision AI for Survivorship and Supportive Care, aims to personalize evidence-based support for cancer survivors navigating persistent side effects and other challenges after treatment. The platform uses machine-learning models to identify patterns associated with symptom burden and unplanned healthcare utilization...

SourceUniversity of Miami Miller School of Medicine·JournalTranslational Behavioral Medicine·DateSep 29, 2026

Five-treatment radiation therapy offers effective nonsurgical alternative for localized prostate cancer

A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...

China reports real-world surgical outcomes for 6,297 pancreatic cancer patients

A Chinese registry report presents real-world perioperative and survival outcomes for surgically treated pancreatic cancer patients, achieving high overall survival rates and encouraging surgical safety metrics. The study emphasizes the need for national-level benchmarks and standardized clinical protocols for pancreatic surgery in China.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalJournal of Pancreatology·TypeData/statistical analysis·DateSep 25, 2026

Weill Cornell Medicine fall grants roundup

Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...

AI model uses routine imaging to identify patients at risk for serious treatment-induced lung inflammation

Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal for ImmunoTherapy of Cancer·DateSep 24, 2026

There’s no one-size-fits-all for treating older adults with cancer, according to new NCCN patient resource

The new NCCN Guidelines for Patients with Cancer explain the importance of assessments to tailor cancer care to every person, regardless of age. The guidelines stress the need for support and validation for older adults, who face unique issues such as memory function and treatment interactions with other medications and conditions.

Rare Coombs-negative hemolytic anemia reported following pembrolizumab treatment

A new case report describes a 68-year-old woman with stage IV lung adenocarcinoma who developed severe hemolysis after receiving pembrolizumab, despite a negative Coombs test. The patient's hemoglobin declined from 11-12 g/dL to 6.4 g/dL, and laboratory markers of hemolysis improved with corticosteroid treatment. The case highlights th...

SourceImpact Journals LLC·JournalOncoscience·TypeCase study·DateSep 10, 2026

Pembrolizumab plus chemotherapy for cervical cancer

The study confirms the durability of benefit for pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer. This treatment regimen has been shown to provide a significant advantage over traditional chemotherapy in patients with this type of cancer.

SourceJAMA Network·JournalJAMA Oncology·DateSep 10, 2026

Restoring MHC-I expression could strengthen immune responses against CNS cancers

Researchers explored strategies to restore MHC-I expression in CNS cancers to make them more visible to the immune system. Approaches include epigenetic therapies, AAV vectors, PCSK9 inhibition, and modifying the tumor microenvironment. However, efficient delivery, antigen processing, and a limited neoantigen repertoire remain signific...

SourceImpact Journals LLC·JournalOncotarget·TypeLiterature review·DateSep 9, 2026

New study identifies a vulnerability in small cell lung cancer – potential therapeutic approach via targeted inhibition

A study from the University of Cologne identified a critical dependency in small cell lung cancer that can be exploited therapeutically. Targeted inhibition of the NMD pathway offers a promising approach to treat SCLC by accumulating mutated proteins and presenting abnormal peptides on the cell surface, making it detectable to the immu...

SourceUniversity of Cologne·JournalMolecular Cancer·TypeExperimental study·DateSep 9, 2026

JMIR news: Looking towards the future of health tech

Recent health tech advancements include drone delivery for organ transportation, AI tools in education with potential risks to childhood development, and early cancer neurotechnology research. Consumer wearables are shifting towards data interpretation, with wearable platforms needed to provide meaningful insights from collected data.

SourceJMIR Publications·JournalJournal of Medical Internet Research·TypeNews article·DateSep 4, 2026

Adjuvant immunotherapy shows no survival benefit for NSCLC patients achieving pCR after neoadjuvant treatment

A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeObservational study·DateSep 2, 2026

Tumor-derived extracellular vesicles show promise for earlier detection of metastatic risk

Tumor-derived extracellular vesicles exhibit intrinsic organotropism and participate in establishing premetastatic niches, making them promising vehicles for targeted imaging probe delivery. However, current imaging approaches have limitations, including difficulty distinguishing between tumor-derived EVs and normal host cell-derived EVs.

SourceImpact Journals LLC·JournalOncotarget·TypeLiterature review·DateSep 1, 2026

Team develops sample preparation method for large-scale glycoproteomics

A research team has developed a reliable and economical method for studying proteins with sugar molecules attached to them in blood and tissue samples. The method uses commercially available magnetic particles and has the potential to aid in disease diagnosis and treatment.

SourceInstitute for Glyco-core Research (iGCORE), Tokai National Higher Education and Research System·JournalMolecular & Cellular Proteomics·TypeExperimental study·DateSep 1, 2026

Rapid development of immunotherapy for gynecological tumors: How to achieve overtaking on the curve?

Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateAug 31, 2026

Targeting LRG1 could open new paths for cancer therapy

A review suggests targeting LRG1 could provide a new approach to cancer therapy, with extracellular blockade and intracellular degradation potentially addressing different components of LRG1 biology. This could complement established anti-angiogenic treatments and enhance apoptosis in cancer cells.

SourceImpact Journals LLC·JournalOncoscience·TypeNews article·DateAug 26, 2026

Standard breast cancer classification may overlook important differences

A new study from Karolinska Institutet suggests that breast cancer classification may overlook important biological differences between patients that could affect treatment decisions. Women with tumours having low to moderate levels of estrogen receptors have poorer survival rates, highlighting the importance of precise classification.

SourceKarolinska Institutet·JournalThe Lancet Regional Health - Europe·TypeObservational study·DateAug 26, 2026

Standard tests can miss “chemobrain” memory issues

A new study found that standard memory tests, such as word-pair or list-learning tests, may fail to detect the real-life memory problems reported by many female breast cancer survivors after chemotherapy. Story-based tests, on the other hand, revealed significant memory difficulties in these women.

SourceDe Gruyter Brill·JournalTranslational Neuroscience·TypeObservational study·DateAug 25, 2026

A ray of hope in the fight against cancer

CDK inhibitors show great potential for cancer treatment, particularly for aggressive tumor types like leukemias, breast, lung, and ovarian cancer. Innovative technologies like PROTACs and molecular glues may further enhance efficacy when combined with existing therapies.

SourceUniversitatsklinikum Bonn·JournalNature Reviews Drug Discovery·DateAug 24, 2026

Federal and industry sponsorship in US cancer clinical trials

A comparative study of 11,681 US cancer clinical trials reveals that industry-sponsored trials focus on single-agent drug therapies, while federally sponsored trials evaluate nontreatment interventions and rare cancer therapies. The study highlights the differences in trial design and objectives between industry and federal funding.

SourceJAMA Network·JournalJAMA Oncology·DateAug 20, 2026

Thyroid lobectomy vs. total thyroidectomy in indeterminate molecular risk thyroid cancer: A randomized clinical trial

The study aimed to determine the proportion of eligible patients consenting to either thyroid lobectomy or total thyroidectomy. It found that 93.5% of patients who would consent to randomization completed the assigned surgery. The results provide valuable insights for targeting enrollment in future multicenter trials.

SourceJAMA Network·JournalJAMA Otolaryngology–Head & Neck Surgery·DateAug 20, 2026